You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

What’s New in the Drug Formulary

All new and recently updated drug and regimen monographs, patient information sheets, as well as safety and advice documents are available here.

Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bendamustine NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:
Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info
Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bortezomib compassionate funding source

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed prior authorization for bendamustine funding

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed "Unfunded" info from bendamustine

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses and Pregnancy/Lactation sections, Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:
Regimen Monograph: Modified Rationale/uses section; Removed bendamustine NDFP funding info
Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed "Unfunded" info from bendamustine

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bendamustine NDFP funding info

Updated
Mar 2026

Pages